Irbesartan angiotensin-receptor blockers
systematic review meta-analysis network meta-analysis
 

Karvea - Avapro - Aprovel      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathmyocardial infarction (fatal and non fatal)

atrial fibrillation  

Madrid, 2002     irbesartancontrolsuggesting
ACTIVE I, 2009    NCTirbesartanplaceboLow risk of bias suggesting5%

diabetes type 2  

IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%

diabetic kidney disease  

IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%

heart failure  

I-PRESERVE (McMurray), 2008      NCTibesartanplaceboLow risk of bias negative2%
Tonkon et al., 2000   irbesartan+ACE inhibitorACE inhibitor onlyLow risk of bias -

heart failure with preserved LVEF  

I-PRESERVE (McMurray), 2008      NCTibesartanplaceboLow risk of bias negative2%

hypertension  

IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%-6%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%-49%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%

miscellaneous  

IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%-6%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%-49%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons